Novartis AG is going to follow up on a fast FDA approval for its first-in-class angiotensin receptor/neprilysin inhibitor Entresto (sacubitril/valsartan) with a fast launch.
Novartis Plans Fast Entresto Launch Following FDA Approval
The company’s first-in-class angiotensin receptor neprilysin inhibitor was approved by FDA for heart failure with reduced ejection fraction July 7, earlier than expected.